This expert opinion review aims to provide practical guidance for implementing adjuvant CDK4/6 inhibitor treatment for patients with HR+, HER2− early-stage breast cancer, incorporating multidisciplinary perspectives from medical and surgical oncologists, a nurse practitioner (NP), an oncology pharmacist, and a patient group representative to maximize successful use of these therapies in Canada. Here, HR is linked to breast carcinoma.